---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-061599"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2022-05-17T23:59:59+00:00"
generated_at: "2026-06-25T12:23:11.787219+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aprea completes acquisition of Atrin; appoints Oren Gilad as CEO, new directors

## Summary
- Issued 1,117,394 common shares and 2,949,630 Series A Preferred (each convertible into 10 common) to Atrin securityholders.
- Certain stockholders agreed to 180-day lock-up on sale of shares received in merger.
- CVRs entitle Aprea legacy holders to cash from disposition of mutant p53 assets within 2 years.
- Oren Gilad appointed President, to become CEO; Christian Schade to stay as Executive Chairman for 6 months.
- Aprea notified Nasdaq of audit committee vacancy due to director resignation; intends to regain compliance.

## SEC filing metadata
- accession: 0001104659-22-061599
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2022-05-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-061599
- JSON: https://secwatch.observer/filing/0001104659-22-061599.json
- Plain text: https://secwatch.observer/filing/0001104659-22-061599.txt

## Key facts
- Executive change
  Fouad Namouni resigned as Director at Aprea Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Rif Pamukcu was appointed as Director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Michael Grissinger was appointed as Director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Michael Grissinger and Rif Pamukcu were appointed as Class II directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Michael A. Kelly resigned as Director at Aprea Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Greg Korbel was appointed as Chief Operating Officer at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: the appointment of Greg Korbel to the position of the Chief Operating Officer of Aprea
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Oren Gilad was appointed as Chief Executive Officer at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective as of the conclusion of the Stockholders’ Meeting, Dr. Gilad will be appointed to the position of Chief Executive Officer of Aprea, to fill the vacancy created by Christian S. Schade’s resignation as Chief Executive Officer of Aprea
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Christian S. Schade resigned as Chief Executive Officer at Aprea Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Effective as of the conclusion of the Stockholders’ Meeting, Christian S. Schade will resign as Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Oren Gilad was appointed as President at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: President
  source text: the appointment of Oren Gilad, Ph.D. to the position of the President of Aprea
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Marc Duey was appointed as Director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Marc Duey was appointed as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
- Executive change
  Oren Gilad was appointed as Director at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Dr. Gilad was appointed as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.